The association between serum irisin levels and cardiovascular disease in diabetic patients.


Journal

Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250

Informations de publication

Date de publication:
Historique:
received: 30 10 2018
accepted: 29 11 2018
entrez: 16 1 2019
pubmed: 16 1 2019
medline: 26 4 2019
Statut: ppublish

Résumé

Cardiovascular disease is the most common cause of mortality and morbidity in diabetic patients. Insulin resistance has been shown to be reduced by the secretion of irisin from muscle and adipose tissues. This study was aimed at determining the relationship between serum irisin levels and angiographically defined coronary artery disease (CAD) in type II diabetic patients. In this case-control study, 30 diabetic subjects with angiographically defined CAD were compared with 30 age- and sex-matched diabetic subjects without CAD in terms of clinical and laboratory parameters including serum irisin levels. Serum levels of Irisin were significantly higher in the diabetic group without CAD compared with the group with CAD (P = 0.048). Serum irisin levels showed a significant positive correlation with BMI (r = 0.374, P = 0.004) and fasting insulin (r = 0.303, P = 0.021), and a significant negative correlation with diabetes duration (r = -0.384, P = 0.002). Based on the results of the binary logistic regression model, circulating levels of irisin were associated with the presence of CAD in diabetes (p = 0.038) after adjusting for potential confounders. Serum irisin levels were lower in the diabetic patients with cardiovascular complication compared with the uncomplicated diabetic patients. Therefore, additional larger scale studies are needed to determine the role of irisin in monitoring CAD in diabetic patients.

Sections du résumé

BACKGROUND BACKGROUND
Cardiovascular disease is the most common cause of mortality and morbidity in diabetic patients. Insulin resistance has been shown to be reduced by the secretion of irisin from muscle and adipose tissues. This study was aimed at determining the relationship between serum irisin levels and angiographically defined coronary artery disease (CAD) in type II diabetic patients.
METHODS METHODS
In this case-control study, 30 diabetic subjects with angiographically defined CAD were compared with 30 age- and sex-matched diabetic subjects without CAD in terms of clinical and laboratory parameters including serum irisin levels.
RESULTS RESULTS
Serum levels of Irisin were significantly higher in the diabetic group without CAD compared with the group with CAD (P = 0.048). Serum irisin levels showed a significant positive correlation with BMI (r = 0.374, P = 0.004) and fasting insulin (r = 0.303, P = 0.021), and a significant negative correlation with diabetes duration (r = -0.384, P = 0.002). Based on the results of the binary logistic regression model, circulating levels of irisin were associated with the presence of CAD in diabetes (p = 0.038) after adjusting for potential confounders.
CONCLUSION CONCLUSIONS
Serum irisin levels were lower in the diabetic patients with cardiovascular complication compared with the uncomplicated diabetic patients. Therefore, additional larger scale studies are needed to determine the role of irisin in monitoring CAD in diabetic patients.

Identifiants

pubmed: 30641808
pii: S1871-4021(18)30515-0
doi: 10.1016/j.dsx.2018.11.050
pii:
doi:

Substances chimiques

Biomarkers 0
FNDC5 protein, human 0
Fibronectins 0
Insulin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

786-790

Informations de copyright

Copyright © 2018 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Auteurs

Zahra Mazloum Khorasani (ZM)

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Ramin Khameneh Bagheri (RK)

Department of Cardiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Mohammad Ali Yaghoubi (MA)

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Birjand University of Medical Sciences, Birjand, Iran.

Saeed Chobkar (S)

School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: chobkar.saeed@gmail.com.

Monavvar Afzal Aghaee (MA)

Department of Social Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Mohammad Reza Abbaszadegan (MR)

Department of Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Amirhossein Sahebkar (A)

Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH